Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Biochem Cell Biol ; 91(2): 79-87, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23527636

RESUMO

Pitx3 has been identified as the causative locus in a developmental eye mutation associated with mammalian anterior segment dysgenesis, congenital cataracts, and aphakia. In recent studies of frog eye development we discovered that pitx3 expresses symmetrically in the somites and lateral plate mesoderm and asymmetrically during cardiac and gut looping. We report that disruption of pitx3 activity on one side of an embryo relative to the other, either by over- or underexpression of pitx3, elicits a crooked dorsal axis in embryos that is a consequence of a retarded progression through somitogenesis. Unlike in amniotes, Xenopus somites form as cohorts of presomitic cells that rotate perpendicular to the dorsal axis. Since no vertebral anomalies have been reported in mouse and human Pitx3 mutants, we attempt to distinguish whether the segmentation clock is uniquely affected in frog or if the pitx3 perturbation inhibits the cellular changes that are necessary to rotation of presomitic cells. In Xenopus, pitx3 appears to inhibit the rotation of presomitic cell cohorts and to be necessary to the bilaterally symmetric expression of pitx2 in somites.


Assuntos
Padronização Corporal/genética , Regulação da Expressão Gênica no Desenvolvimento , Organogênese/genética , Somitos/metabolismo , Fatores de Transcrição/genética , Proteínas de Xenopus/genética , Xenopus laevis/genética , Animais , Embrião não Mamífero , Lateralidade Funcional/genética , Humanos , Camundongos , Mutação , Somitos/embriologia , Fatores de Transcrição/metabolismo , Proteínas de Xenopus/metabolismo , Xenopus laevis/embriologia , Xenopus laevis/metabolismo
2.
Dev Dyn ; 241(9): 1487-505, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22826267

RESUMO

BACKGROUND: Unexpected phenotypes resulting from morpholino-mediated translational knockdown of Pitx3 in Xenopus laevis required further investigation regarding the genetic networks in which the gene might play a role. Microarray analysis was, therefore, used to assess global transcriptional changes downstream of Pitx3. RESULTS: From the large data set generated, selected candidate genes were confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) and in situ hybridization. CONCLUSIONS: We have identified four genes as likely direct targets of Pitx3 action: Pax6, ß Crystallin-b1 (Crybb1), Hes7.1, and Hes4. Four others show equivocal promise worthy of consideration: Vent2, and Ripply2 (aka Ledgerline or Stripy), eFGF and RXRα. We also describe the expression pattern of additional and novel genes that are Pitx3-sensitive but that are unlikely to be direct targets.


Assuntos
Regulação da Expressão Gênica no Desenvolvimento , Genes Controladores do Desenvolvimento/genética , Fatores de Transcrição/fisiologia , Proteínas de Xenopus/fisiologia , Xenopus laevis/embriologia , Xenopus laevis/genética , Animais , Análise por Conglomerados , Embrião não Mamífero , Desenvolvimento Embrionário/genética , Olho/embriologia , Olho/metabolismo , Hibridização In Situ , Botões de Extremidades/embriologia , Botões de Extremidades/metabolismo , Análise em Microsséries , Cauda/embriologia , Cauda/metabolismo , Fatores de Transcrição/genética , Fatores de Transcrição/metabolismo , Transcriptoma , Proteínas de Xenopus/genética , Proteínas de Xenopus/metabolismo
3.
Food Drug Law J ; 67(2): 131-41, i, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-24620416

RESUMO

Biological drug products are poised to overtake traditional pharmaceuticals as the best selling products in the pharmaceutical industry. Accordingly, both innovator and generic drug companies have a vested interest in the rules and regulations governing the approval and market entry of follow-on ("generic") biologic drug products as well as relevant procedures for litigating disputes involving biologic drug products. The U.S. and Canada both regulate the development and sale of traditional generic drugs through complex legal and regulatory schemes that seek to maintain a balance of interests between the innovator and generic sectors of the pharmaceutical industry. With the continued emergence of biological drugs, both countries have recently set forth legal and regulatory schemes to address the unique issues presented by generic biologic drug products. These issues include the requirements needed to submit an application for a generic biologic; biosimilarity vs. interchangeability designations; market and data exclusivity; and procedures for litigating disputes involving biologic drugs. Like the respective rules governing traditional pharmaceuticals, the recent U.S. and Canadian regulations addressing biological drugs contain both similarities and differences. As such, an understanding of both countries regulatory schemes will help both innovators and generics in decision making and legal strategy related to biological drugs. This article provides a comparative overview of the two systems to assist in such an understanding.


Assuntos
Produtos Biológicos , Medicamentos Biossimilares , Medicamentos Genéricos , Legislação de Medicamentos , Canadá , Aprovação de Drogas/legislação & jurisprudência , Humanos , Patentes como Assunto , Estados Unidos
4.
Int J Dev Biol ; 53(7): 1063-7, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19598124

RESUMO

We have cloned and characterized a second member of the Xenopus CAP (cyclase associated protein) gene family. xCAP2 demonstrates greater restriction of expression than its homolog, xCAP1, and is differentially expressed throughout early embryogenesis. Although present as a maternal transcript, CAP2 comes to be expressed in the anterior-most mesoderm/endoderm during late gastrulation, in paraxial mesoderm during late neurula stages, and later expresses in lens, cardiac primordia, somites, otic vesicles, retina, and in the optic and craniofacial musculature. The gene is also expressed in the leading edge of myotome.


Assuntos
Proteínas de Xenopus/genética , Xenopus laevis/embriologia , Xenopus laevis/genética , Sequência de Aminoácidos , Animais , Sequência de Bases , Clonagem Molecular , Primers do DNA/genética , Desenvolvimento Embrionário/genética , Gastrulação/genética , Regulação da Expressão Gênica no Desenvolvimento , Hibridização In Situ , Dados de Sequência Molecular , Família Multigênica , Filogenia , Homologia de Sequência de Aminoácidos , Xenopus laevis/metabolismo
5.
Genesis ; 47(1): 19-31, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19006070

RESUMO

The aristaless-related gene, Arx, plays a fundamental role in patterning the brain in humans and mice. Arx mutants exhibit lissencephaly among other anomalies. We have cloned a Xenopus aristaless homolog that appears to define specific regions of the developing forebrain. xArx2 is transcribed in blastula through neurula stages, and comes to be restricted to the ventral and lateral telencephalon, lateral diencephalon, neural floor plate of the anterior spinal cord, and somites. In this respect, Arx2 expresses in regions similar to Arx with the exception of the somites. Overexpression enlarges the telencephalon, and interference by means of antisense morpholino-mediated translation knockdown reduces growth of this area. Overexpression and inhibition studies demonstrate that misregulation of xArx2 imposes dire consequences upon patterns of differentiation not only in the forebrain where the gene normally expresses, but also in more caudal brain territories and derivatives as well. This suggests that evolutionary changes that expanded Arx-expression from ventral to dorsal prosencephalon might be one of the determinants that marked development and expansion of the telencephalon.


Assuntos
Encéfalo/embriologia , Encéfalo/metabolismo , Fatores de Transcrição/metabolismo , Proteínas de Xenopus/metabolismo , Xenopus laevis/embriologia , Xenopus laevis/metabolismo , Sequência de Aminoácidos , Animais , Encéfalo/crescimento & desenvolvimento , Sequência Conservada , Embrião não Mamífero/embriologia , Embrião não Mamífero/metabolismo , Regulação da Expressão Gênica no Desenvolvimento , Humanos , Hibridização In Situ , Dados de Sequência Molecular , Filogenia , Biossíntese de Proteínas/genética , RNA Mensageiro/genética , Alinhamento de Sequência , Fatores de Transcrição/química , Fatores de Transcrição/classificação , Fatores de Transcrição/genética , Proteínas de Xenopus/química , Proteínas de Xenopus/classificação , Proteínas de Xenopus/genética , Xenopus laevis/genética , Xenopus laevis/crescimento & desenvolvimento
6.
Dev Dyn ; 234(3): 577-89, 2005 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16170783

RESUMO

Pitx3 is expressed in tissues fated to contribute to eye development, namely, neurula stage ectoderm and pre-chordal mesoderm, then presumptive lens ectoderm, placode, and finally lens. Pitx3 overexpression alters lens, optic cup, optic nerve, and diencephalon development. Many of the induced anomalies are attributable to midline deficits; however, as assessed by molecular markers, ectopic Pitx3 appears to temporarily enlarge the lens field. These changes are usually insufficient to generate either ectopic lenses to enlarge the eye that eventually differentiates. Conversely, use of a repressor chimera or of antisense morpholinos alters early expression of marker genes, and later inhibits lens development, thereby abrogating retinal induction. Reciprocal grafting experiments using wild-type and morpholino-treated tissues demonstrate that Pitx3 expression in the presumptive lens ectoderm is required for lens formation. Contradictory to recent assertions that retina can form in the absence of a lens, the expression of Pitx3 in the presumptive lens ectoderm is critical for retina development.


Assuntos
Ectoderma/metabolismo , Cristalino/embriologia , Cristalino/metabolismo , Retina/embriologia , Retina/metabolismo , Fatores de Transcrição/metabolismo , Proteínas de Xenopus/metabolismo , Xenopus laevis/embriologia , Animais , Biomarcadores , Clonagem Molecular , DNA Complementar/genética , Embrião não Mamífero/embriologia , Embrião não Mamífero/metabolismo , Regulação da Expressão Gênica no Desenvolvimento , Fatores de Tempo , Fatores de Transcrição/genética , Proteínas de Xenopus/genética , Xenopus laevis/genética , Xenopus laevis/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...